blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3154586

EP3154586 - TREATING LYMPHOMAS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.04.2021
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  24.04.2020
FormerGrant of patent is intended
Status updated on  17.12.2019
FormerExamination is in progress
Status updated on  21.09.2018
FormerRequest for examination was made
Status updated on  20.03.2017
FormerThe international publication has been made
Status updated on  21.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Mayo Foundation for Medical Education and Research
200 First Street S.W.
Rochester, MN 55905 / US
[2017/16]
Inventor(s)01 / MARKOVIC, Svetomir N.
1320 Creek Lane S.W.
Rochester Minnesota 55902 / US
02 / NEVALA, Wendy K.
71 N. River Court N.E.
Rochester Minnesota 55906 / US
 [2017/16]
Representative(s)Gibson, Mark
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[2020/22]
Former [2017/16]Gibson, Mark
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
Application number, filing date15806443.612.06.2015
[2017/16]
WO2015US35505
Priority number, dateUS201462012190P13.06.2014         Original published format: US 201462012190 P
[2017/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015191969
Date:17.12.2015
Language:EN
[2015/50]
Type: A1 Application with search report 
No.:EP3154586
Date:19.04.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 17.12.2015 takes the place of the publication of the European patent application.
[2017/16]
Type: B1 Patent specification 
No.:EP3154586
Date:27.05.2020
Language:EN
[2020/22]
Search report(s)International search report - published on:US17.12.2015
(Supplementary) European search report - dispatched on:EP11.12.2017
ClassificationIPC:A61K39/395, A61K31/555, A61P35/00
[2018/02]
CPC:
A61K31/282 (EP,IL,KR,US); A61K9/0019 (IL,KR,US); A61K31/555 (IL,KR,RU);
A61K39/3955 (EP,IL,KR,US); A61K31/337 (EP,IL,KR,US); A61K38/38 (EP,IL,KR,US);
A61K39/395 (IL,RU); A61K47/643 (EP,IL,KR,US); A61K47/6803 (KR);
A61K47/6849 (EP,IL,KR,US); A61K47/6929 (EP,IL,KR,US); A61P35/00 (EP,IL,KR,RU);
C07K16/2887 (EP,IL,KR,US); C07K16/30 (IL,KR,US); A61K2039/505 (EP,IL,KR,US);
A61K2039/54 (EP,IL,KR,US); A61K2039/545 (EP,IL,KR,US); C07K2317/24 (EP,IL,KR,US) (-)
C-Set:
A61K38/38, A61K2300/00 (US,EP);
A61K39/3955, A61K2300/00 (EP,US)
Former IPC [2017/16]A61K39/395, A61K31/555
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/16]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:BEHANDLUNG VON LYMPHOMEN[2017/16]
English:TREATING LYMPHOMAS[2017/16]
French:TRAITEMENT DE LYMPHOMES[2017/16]
Entry into regional phase21.12.2016National basic fee paid 
21.12.2016Search fee paid 
21.12.2016Designation fee(s) paid 
21.12.2016Examination fee paid 
Examination procedure21.12.2016Examination requested  [2017/16]
21.12.2016Date on which the examining division has become responsible
10.07.2018Amendment by applicant (claims and/or description)
24.09.2018Despatch of a communication from the examining division (Time limit: M04)
04.01.2019Reply to a communication from the examining division
04.11.2019Cancellation of oral proceeding that was planned for 12.11.2019
12.11.2019Date of oral proceedings (cancelled)
18.12.2019Communication of intention to grant the patent
17.04.2020Fee for grant paid
17.04.2020Fee for publishing/printing paid
17.04.2020Receipt of the translation of the claim(s)
Opposition(s)02.03.2021No opposition filed within time limit [2021/18]
Fees paidRenewal fee
27.06.2017Renewal fee patent year 03
27.06.2018Renewal fee patent year 04
27.06.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.06.2015
AL27.05.2020
AT27.05.2020
CY27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
MK27.05.2020
MT27.05.2020
NL27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
TR27.05.2020
LU12.06.2020
BE30.06.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
[2022/32]
Former [2022/27]HU12.06.2015
AL27.05.2020
AT27.05.2020
CY27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
MT27.05.2020
NL27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
TR27.05.2020
LU12.06.2020
BE30.06.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/24]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
NL27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
LU12.06.2020
BE30.06.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/15]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
NL27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SK27.05.2020
SM27.05.2020
LU12.06.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/13]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
NL27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/10]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
NL27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/09]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
NL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SM27.05.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/08]AL27.05.2020
DK27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
NL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SM27.05.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/04]AL27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
NL27.05.2020
RS27.05.2020
SE27.05.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/01]FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
RS27.05.2020
SE27.05.2020
BG27.08.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/51]FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
RS27.05.2020
SE27.05.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/50]FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
SE27.05.2020
NO27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/48]FI27.05.2020
LT27.05.2020
SE27.05.2020
NO27.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/47]LT27.05.2020
NO27.08.2020
IS27.09.2020
Former [2020/46]IS27.09.2020
Documents cited:Search[Y] WO2012154861  (MAYO FOUNDATION et al.) [Y] 1-15 * examples 6,7 *
 [A] WO2014055415  (MAYO FOUNDATION et al.) [A] 1-15 * example - *
 [A] WO2008057561  (DOW AGROSCIENCES LLC et al.) [A] 1-15 * examples 11,15,18,25-27,29-32 *
 [Y]   NELLY MEZZAROBA ET AL: "New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles", PLOS ONE, vol. 8, no. 9, 30 September 2013 (2013-09-30), pages e74216, XP055245034, DOI: 10.1371/journal.pone.0074216 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0074216
International search[XY] WO2012048223  (ABRAXIS BIOSCIENCE LLC et al.) [X] 1-3, 5-12, 16 * para [0009], [0018], [0057], [0061], [0065], [0066], [0067], [0070], [0074], [0075], [0079],[00100] *[Y] 4, 13-15, 17-72
 [Y] WO2014055415  (MAYO FOUNDATION et al.) [Y] 4, 13-15, 17-72 * claims 63-72, pg 2, In 14-27, pg 3, In 17-24, In 27-29, pg 4, In 7-23, In 25-28, pg 25, In 2-7 *
 [Y] US2011076273  (ADLER MICHAEL et al.) [Y] 19-20, 45-46 * para [0015], [0078], [0193]-[0195] *
 [A]   MEZZAROBA ET AL.: "New potential therapeutic approach for the treatment of B- Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti- CD 20 nanoparticles", PLOS ONE, vol. 8, no. 9, 30 September 2013 (2013-09-30), pages 1 - 10, XP055245034 [A] 1 * ; abstract *

DOI:   http://dx.doi.org/10.1371/journal.pone.0074216
 [A]   WAGNER ET AL.: "Enhanced drug targeting by attachment of an anti-alpha.v integrin antibody to doxorubicin loaded human serum albumin nanoparticles", BIOMATERIALS, vol. 31, no. 8, March 2010 (2010-03-01), pages 2388 - 2398, XP026870608 [A] 1 * ; abstract *
Examination  WASHINGTON UNIVERSITY SCHOOL OF MEDICINE: "Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma NCT01555853", CLINICALTRIALS.GOV, 16 March 2012 (2012-03-16), XP055430450, Retrieved from the Internet [retrieved on 20171130]
   DU FANNY HUYNH ET AL: "Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment", AUTOIMMUNITY HIGHLIGHTS, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 8, no. 1, 16 November 2017 (2017-11-16), pages 1 - 12, XP036380018, ISSN: 2038-0305, [retrieved on 20171116], DOI: 10.1007/S13317-017-0100-Y [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1007/s13317-017-0100-y
   BRADLEY J. MONK ET AL: "Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?", GYNECOLOGIC ONCOLOGY RESEARCH AND PRACTICE, vol. 4, no. 1, 21 March 2017 (2017-03-21), XP055579052, DOI: 10.1186/s40661-017-0045-x

DOI:   http://dx.doi.org/10.1186/s40661-017-0045-x
   "Guideline on similar biological medicinal products contianing biotechnology-derived proteins as active substance: non-clinical and clinical issues", 18 December 2014, article COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: "Guideline on similar biological medicinal products contianing biotechnology-derived proteins as active substance: non-clinical and clinical issues", XP055579065
   FDA: "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product", GUIDANCE FOR INDUSTRY, 1 February 2012 (2012-02-01), XP055180486
   "Truxima, rituximab", 1 February 2017, article EPAR SUMMARY FOR THE PUBLIC: "Truxima, rituximab", XP055579085 [DP]
by applicantWO2014055415
 US5736137
 US6537579
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.